Ponvory (Ponesimod) Patent Expiration, LOE Window & CMS Spending

Ponvory (Ponesimod) by Vanda: FDA Orange Book core substance LOE 2032-05-06 (last listed 2044-12-24), 0 AB generics, $8.9M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVanda
FDA Application & PathwayN213498 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-05-06
Last Listed Patent or Exclusivity Date2044-12-24
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$8.9M
2024 Medicare Part D Spend$6.4M
2024 Medicaid Spend$2.6M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 18.4% 2-yr change)